Exact Sciences Corporation $EXAS Shares Bought by Dimensional Fund Advisors LP

Key Points

• Dimensional Fund Advisors LP raised its stake in Exact Sciences by 12.3% in Q3, buying 239,313 shares to own 2,188,864 shares (about 1.16%) worth roughly $119.7 million, and institutional investors now hold about 88.82% of the company.
• Exact Sciences posted a 23.1% year-over-year revenue increase but missed quarterly EPS (‑$0.21 vs $0.08 consensus), leaving the company with a negative PE (‑94.0) despite a $19.7 billion market cap.
• Analyst sentiment is cautious — MarketBeat shows a consensus rating of “Reduce” with a $92.13 price target, while the stock trades near $103.40 (52-week range $38.81–$103.75).

Dimensional Fund Advisors LP raised its position in shares of Exact Sciences Corporation (NASDAQ:EXAS - Free Report) by 12.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,188,864 shares of the medical research company's stock after buying an additional 239,313 shares during the period. Dimensional Fund Advisors LP owned about 1.16% of Exact Sciences worth $119,732,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of the company. Integrated Wealth Concepts LLC purchased a new position in Exact Sciences during the 1st quarter valued at about $604,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Exact Sciences by 11.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,186 shares of the medical research company's stock worth $921,000 after purchasing an additional 2,231 shares in the last quarter. Great Lakes Advisors LLC boosted its stake in shares of Exact Sciences by 3.7% in the first quarter. Great Lakes Advisors LLC now owns 4,971 shares of the medical research company's stock valued at $215,000 after purchasing an additional 178 shares during the period. Focus Partners Wealth boosted its stake in shares of Exact Sciences by 12.6% in the first quarter. Focus Partners Wealth now owns 21,548 shares of the medical research company's stock valued at $933,000 after purchasing an additional 2,413 shares during the period. Finally, Campbell & CO Investment Adviser LLC acquired a new position in shares of Exact Sciences in the second quarter valued at approximately $1,516,000. 88.82% of the stock is owned by institutional investors and hedge funds.

Exact Sciences Trading Up 0.0%

NASDAQ EXAS opened at $103.40 on Thursday. Exact Sciences Corporation has a 52 week low of $38.81 and a 52 week high of $103.75. The firm has a 50 day moving average of $102.76 and a two-hundred day moving average of $83.06. The company has a quick ratio of 2.17, a current ratio of 2.43 and a debt-to-equity ratio of 0.97. The stock has a market capitalization of $19.74 billion, a PE ratio of -94.00, a price-to-earnings-growth ratio of 2.35 and a beta of 1.41.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its quarterly earnings data on Friday, February 13th. The medical research company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of $0.08 by ($0.29). Exact Sciences had a negative net margin of 6.40% and a positive return on equity of 0.53%. The company's revenue for the quarter was up 23.1% on a year-over-year basis. During the same quarter last year, the business earned ($0.06) earnings per share. As a group, research analysts expect that Exact Sciences Corporation will post -0.58 EPS for the current fiscal year.

Analysts Set New Price Targets

EXAS has been the topic of a number of research reports. Citigroup lowered shares of Exact Sciences from a "buy" rating to a "hold" rating in a report on Thursday, November 20th. Piper Sandler downgraded shares of Exact Sciences from an "overweight" rating to a "hold" rating and set a $105.00 price target for the company. in a research note on Monday, November 24th. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $105.00 price objective (up from $85.00) on shares of Exact Sciences in a research report on Thursday, November 20th. Stifel Nicolaus reiterated a "hold" rating and issued a $105.00 price objective (up from $80.00) on shares of Exact Sciences in a research note on Friday, November 28th. Finally, Barclays reissued an "equal weight" rating and set a $105.00 target price (up from $77.00) on shares of Exact Sciences in a research note on Thursday, November 20th. Twenty-one equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Exact Sciences presently has a consensus rating of "Reduce" and a consensus price target of $92.13.

Exact Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company's flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.